Beckman Coulter Diagnostics appoints Catherine Jennings as president

By Public Technologies
  • Danaher unit Beckman Coulter Diagnostics appointed Catherine “Cat” Jennings as president.
  • Jennings will oversee strategy and operations, with a mandate to accelerate innovation and expand global reach in clinical diagnostics.
  • She joins from Boston Scientific, where she led the Vascular Therapies business, a unit with about USD 2 billion annual revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Danaher Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610140831PR_NEWS_USPR_____LA71682) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.